Tranexamic acid to reduce bleeding during weight-loss surgery
Tests tranexamic acid to limit bleeding in adults having bariatric surgery for obesity.
Plain-language title generated from the registry record
Registry title: Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery
Key facts
- Where
- Karachi, PakistanSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07098780, who can take part
Where in Pakistan
- Patel HospitalKarachi, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Patel Hospital, Pakistan
- Trial code
- NCT07098780
- Record updated
- 1 August 2025
- Original description
The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are:Read full original descriptionShow less
Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery
The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are:
Does TXA reduce the amount of blood loss during bariatric surgery? Are there any side effects or complications in patients who receive TXA? Researchers will compare TXA to standard care (no TXA) to see if it is effective in reducing bleeding.
Participants will:
Receive either TXA or no TXA (placebo) before surgery Undergo standard bariatric surgery (LSG or MGB) Have their blood loss, hemoglobin levels, and any complications monitored during and after surgery
Inclusion: Patients above 18 years of age AND; Undergoing Laparoscopic Sleeve Gastrectomy and MGB; Morbid obesity.
Exclusion: Female hormonal replacement therapy; Patients with inherited or acquired bleeding disorders; Patients with any acute medical condition predisposing to bleeding; Patients on anti-platelets/anti-coagulants; Hormonal contraceptives; Known Allery to TXA.